Raymond James Upgrades Incyte (INCY) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Stocks and yen struggle as tech troubles weigh
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen at multi-decade lows, dollar drops before US data
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Updated Phase 1 Data Reinforce the Clinical Profile of Epacadostat in Combination with Keytruda® (Pembrolizumab)
September 28, 2016 6:11 AM EDTIncytes IDO1 inhibitor in combination with Mercks anti-PD-1 therapy is well-tolerated and demonstrates durable clinical response in patients with treatment-naïve advanced melanoma
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (Nasdaq: INCY) today announced that the European Society for Medical Oncology (ESMO) has published an abstract (#1110PD) containing updated data from the Phase 1 portion of the ECHO-202 trial evaluating the safety and efficacy of epacadostat, Incytes selective IDO1 enzyme inhibitor, in combination with Keytruda® (pembrolizumab), Mercks anti-PD-1 therapy. These data will be highlighted in a poster discussion on... More
NCCN Guidelines® Recommend Jakafi® (ruxolitinib) for the Treatment of Myelofibrosis
September 27, 2016 7:45 AM EDTTreatment guidelines for myeloproliferative neoplasms (MPNs) focused on the treatment of myelofibrosis (MF), a rare blood cancer, published today
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (Nasdaq: INCY) today announced that its first-in-class JAK1/JAK2 inhibitor, Jakafi® (ruxolitinib), has been included as a recommended treatment in the latest National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for myelofibrosis (MF).
Jakafi is the first FDA-approved treatment for patients with intermediate or high-risk MF, representing an important advancement for patients, said Peg... More
